ALIVUSAlivus Life Sciences Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.9 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹682 Cr | ₹197 Cr | 35.69% | 28.85% | ₹16.02 | Negligible |
| Q1 FY2027 | ₹640 Cr | ₹160 Cr | 29.84% | 24.99% | ₹13.04 | 164.2x |
| Q4 FY2026 | ₹689 Cr | ₹163 Cr | 28.20% | 23.60% | ₹13.23 | 167.0x |
| Q3 FY2026 | ₹673 Cr | ₹150 Cr | 31.45% | 22.33% | ₹12.25 | 134.1x |
| Q2 FY2026 | ₹588 Cr | ₹130 Cr | 27.34% | 22.11% | ₹10.60 | 133.9x |
| Q1 FY2026 | ₹602 Cr | ₹122 Cr | 25.79% | 20.19% | ₹9.91 | 131.4x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.